Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

(Instr. 4)

hours per response.

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

may continue. Se Instruction 1(b).	FIICODE	arsuant to Section	` /	urities Excha Company A	_		ection 30(h) of the			
(Print or Type Respons	ses)									
1. Name and Address BAXTER GREGO	1 0	2. Issuer Name an Stellar Biotechno			nbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
C/O STELLAR BI EAST SCOTT STI		TEC DIG 222	3. Date of Earliest T 03/28/2017	ransaction (M	onth/Day/	Year)	X Officer (give title below) Other (specify below) EVP, Corporate Development			
PORT HUENEME	(Street) , CA 93041		4. If Amendment, D	ate Original Fi	iled(Month/	Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person			
(City)	(State)	(Zip)	T	able I - Non-D	erivative	Securities Ac	quired, Disposed of, or Beneficially Ov	vned		
1.Title of Security (Instr. 3)		Date (Month/Day/Year)	Execution Date, if	(Instr. 8)	(A) or			Ownership Form:	7. Nature of Indirect Beneficial Ownership	

(A) or

(Ď)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	Transaction	3A. Deemed	4.		5. Numb	er	Date Exer	rcisable and	7. Title and		8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	tion	of		Expiration I	Date	Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivativ	ve	(Month/Day	/Year)	Underlying		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Securitie	es			Securities		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquired	i			(Instr. 3 and	14)		Owned	Security:	(Instr. 4)
	Security					(A) or							Following	Direct (D)	
	-					Disposed	d of						Reported	or Indirect	
						(D)							Transaction(s)	(I)	
						(Instr. 3,	4,						(Instr. 4)	(Instr. 4)	
						and 5)									
				C. I.	V	(4)		Exercisable	Expiration Date		Amount or Number of Shares				
				Code	V	(A)	(D)				Shares				
Share Option (Right to Buy)	\$ 1.6	03/28/2017		A		10,000		<u>(1)</u>	03/28/2024	Common Shares	10,000	\$ 0	10,000	D	

Reporting Owners

Reporting Owner Name / Address		Relationships							
		10% Owner	Officer	Other					
BAXTER GREGORY T. C/O STELLAR BIOTECHNOLOGIES, INC. 332 EAST SCOTT STREET PORT HUENEME, CA 93041			EVP, Corporate Development						

Signatures

/s/ Kathi Niffenegger, as Attorney-in-Fact	03/29/2017		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third on March 23, 2018, as to one-third on March 23, 2019 and as to the remaining one-third on March 23, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.